The mechanisms of action of metformin on head and neck cancer in the pre-clinical setting: a scoping review

Front Oncol. 2024 Feb 22:14:1358854. doi: 10.3389/fonc.2024.1358854. eCollection 2024.

Abstract

This scoping review identifies the mechanistic pathways of metformin when used to treat head and neck cancer cells, in the pre-clinical setting. Understanding the underlying mechanisms will inform future experimental designs exploring metformin as a potential adjuvant for head and neck cancer. This scoping review was conducted according to the Joanna-Briggs Institute framework. A structured search identified 1288 studies, of which 52 studies fulfilled the eligibility screen. The studies are presented in themes addressing hallmarks of cancer. Most of the studies demonstrated encouraging anti-proliferative effects in vitro and reduced tumor weight and volume in animal models. However, a few studies have cautioned the use of metformin which supported cancer cell growth under certain conditions.

Keywords: cell lines; head and neck cancer; metformin; squamous cell carcinoma; xenograft.

Publication types

  • Systematic Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The primary author is supported by the Passe and Williams Foundation Academic Surgeon-Scientist Research scholarship.